4//SEC Filing
Savill Corrine 4
Accession 0000950170-24-007032
CIK 0001789972other
Filed
Jan 23, 7:00 PM ET
Accepted
Jan 24, 5:00 PM ET
Size
16.2 KB
Accession
0000950170-24-007032
Insider Transaction Report
Form 4
Savill Corrine
Chief Business Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-01-23−21,316→ 13,997 totalExercise: $4.30Exp: 2030-10-28→ Common Stock (21,316 underlying) - Sale
Common Stock
2024-01-22$12.18/sh−14,559$177,329→ 170,115 total - Sale
Common Stock
2024-01-23$12.46/sh−21,316$265,597→ 165,990 total - Exercise/Conversion
Common Stock
2024-01-22$4.30/sh+14,559$62,604→ 184,674 total - Sale
Common Stock
2024-01-22$12.02/sh−4,125$49,583→ 165,990 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-01-22−14,559→ 35,313 totalExercise: $4.30Exp: 2030-10-28→ Common Stock (14,559 underlying) - Exercise/Conversion
Common Stock
2024-01-23$4.30/sh+21,316$91,659→ 187,306 total
Footnotes (5)
- [F1]Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2023.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.44. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.09. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.16 to $12.60. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]25% of the shares vested on May 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on May 4, 2023.
Documents
Issuer
Cullinan Oncology, Inc.
CIK 0001789972
Entity typeother
Related Parties
1- filerCIK 0001837524
Filing Metadata
- Form type
- 4
- Filed
- Jan 23, 7:00 PM ET
- Accepted
- Jan 24, 5:00 PM ET
- Size
- 16.2 KB